Triamterene
| Evidence Level: L5 | Predicted Indications: 6 |
Table of Contents
Triamterene: From Potassium-Sparing Diuretic Use to Malignant Renovascular Hypertension
One-Sentence Summary
Triamterene is a potassium-sparing diuretic that works by blocking the epithelial sodium channel (ENaC) to reduce sodium reabsorption; it currently holds no UK marketing authorisation. The TxGNN model’s top-ranked prediction links it to Malignant Renovascular Hypertension, but this is a model-only prediction (L5) with no supporting clinical trials or literature, and the underlying mechanistic rationale itself flags a significant safety concern — potassium-sparing diuretics may be relatively contraindicated in this condition due to hyperkalaemia risk in the presence of renal impairment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified — no UK marketing authorisation on record; pharmacologically, Triamterene is a potassium-sparing diuretic used for oedema/hypertension management |
| Predicted New Indication | Malignant Renovascular Hypertension |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| UK Market Status | Not Marketed |
| Number of Marketing Authorisations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the formal drug record (flagged as a High-severity data gap). However, the evidence pack’s mechanistic rationale describes Triamterene as a potassium-sparing diuretic that blocks ENaC in the distal nephron, reducing sodium reabsorption and producing a mild antihypertensive effect. On this basis, there is a theoretical, class-level link to hypertensive conditions generally.
However, the specific pathophysiology of malignant renovascular hypertension is driven by renal artery stenosis and marked activation of the renin-angiotensin-aldosterone system (RAAS), typically accompanied by declining renal function. In this setting, a potassium-sparing diuretic carries an elevated risk of hyperkalaemia and may be relatively contraindicated rather than beneficial. The evidence pack itself explicitly characterises this mechanistic link as “weak, with the direction of effect in question.” This should be read as a caution rather than a supportive rationale.
No clinical trials, literature, or real-world evidence for this specific drug-indication pairing were found, so the prediction currently rests entirely on the TxGNN knowledge-graph score.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
UK Market Information
Triamterene has no UK marketing authorisation on record in this evidence pack (market status: Not Marketed; total licences: 0). No product-level dosage form or approved indication text is currently available to summarise here.
Safety Considerations
Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.
Note: The evidence pack flags TFDA/MHRA-equivalent labelling warnings and contraindications as a Blocking data gap (DG001), meaning formal safety screening (S1 stage) cannot proceed until this is resolved. In addition, the mechanistic rationale for the top prediction raises a specific concern about hyperkalaemia risk when potassium-sparing diuretics are used in patients with renovascular disease and reduced renal function — this should be treated as a safety signal requiring clinical review, not merely a data gap.
Other Predicted Indications from This Evidence Pack
This evidence pack scored six candidate indications for Triamterene. For completeness, the other five are summarised below; none currently reach a level of evidence sufficient to support progression beyond a research question.
| Rank | Predicted Indication | TxGNN Score | Evidence Level | Recommendation | Note |
|---|---|---|---|---|---|
| 2 | Malignant hypertensive renal disease | 99.89% | L5 | Hold | Same hyperkalaemia concern as rank 1; no supporting evidence |
| 3 | Pulmonary hypertension (unclear multifactorial mechanism, WHO Group 5) | 99.88% | L5 | Hold | No mechanistic or evidentiary support |
| 4 | Pulmonary hypertension due to lung disease and/or hypoxia (WHO Group 3) | 99.88% | L4 | Research Question | Literature is largely hypoxia/oncology basic-science, not diuretic- or Triamterene-specific; diuretics are a guideline-supported class-effect adjunct for right heart volume overload |
| 5 | Braddock (CHOPS) syndrome | 99.84% | L5 | Hold | No known pathophysiological link; assessed as likely knowledge-graph noise |
| 6 | Chronic pulmonary heart disease (cor pulmonale) | 99.75% | L4 | Research Question | Literature supports diuretics generally (including triamterene-containing combinations) for volume management in chronic heart failure; not indication-specific trial evidence |
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (malignant renovascular hypertension) has no supporting clinical trials or literature (L5, model-score only), and its own mechanistic rationale raises a plausible safety contraindication (hyperkalaemia risk) rather than supporting evidence. Combined with a Blocking data gap on formal drug warnings/contraindications, this candidate does not meet the threshold to proceed.
To proceed, the following is needed:
- TFDA/MHRA-equivalent product labelling (warnings, contraindications) to resolve the Blocking data gap (DG001)
- Confirmed mechanism of action from DrugBank or equivalent primary source (DG002)
- Original licensed indication and regulatory history for Triamterene, to properly frame the “original vs new indication” comparison
- Clinical or pharmacological assessment of hyperkalaemia risk specifically in renovascular/renal-impaired hypertensive populations before any further consideration of ranks 1–2
- If pursuing the more plausible volume-management candidates (ranks 4 and 6), Triamterene-specific (rather than class-level) clinical evidence in pulmonary hypertension/cor pulmonale populations
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.